<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868814</url>
  </required_header>
  <id_info>
    <org_study_id>HR-PRBL-FM</org_study_id>
    <nct_id>NCT02868814</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Pregabalin Release Tablets for the Treatment of Fibromyalgia</brief_title>
  <official_title>The Efficacy and Safety of Pregabalin Release Tablets for the Treatment of Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Efficacy and safety of pregabalin sustained
      release tablets versus placebo for fibromyalgia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean pain score diary at Endpoint</measure>
    <time_frame>Baseline and 15 weeks</time_frame>
    <description>derived from the subject's daily pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FIQ scores at Weeks 15</measure>
    <time_frame>Baseline and Weeks 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SF-36 scores at Weeks 15</measure>
    <time_frame>Baseline and Weeks 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HADS scores at Weeks 15</measure>
    <time_frame>Baseline and Weeks 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MOS-SS scores at Weeks 15</measure>
    <time_frame>Baseline and Weeks 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Sleep Score from the Daily Sleep Diary</measure>
    <time_frame>up to 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pain score from the subject's daily pain</measure>
    <time_frame>up to 15 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>330mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>330 mg QD taken orally,1 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>495mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>495 mg QD taken orally,2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 or 2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin Release Tablets</intervention_name>
    <arm_group_label>330mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin Release Tablets</intervention_name>
    <arm_group_label>495mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who met the 1990 American College of Rheumatology (ACR) criteria for
             fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least
             11 of 18 specific tender point sites).

        Patients who completed at least 4 pain diaries within the last 7 days and the average pain
        score must have been ≥4, and had a score of ≥40 mm on the Visual Analogue Scale (VAS) at
        screening and randomization .

        Exclusion Criteria:

          -  Patients with other severe pain that may confound assessment or self-evaluation of the
             pain associated with fibromyalgia.

        Patients with any inflammatory muscle or rheumatologic disease other than fibromyalgia,
        active infections, or untreated endocrine disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xiehe Hospital of Beijing</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>UN</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu Qingjun, M.D.</last_name>
      <phone>UN</phone>
      <email>wuqingjun@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

